Insider and congress filings
CRISPR Therapeutics AG (CRSP)
Free on iOS and Android.
About CRISPR Therapeutics AG
from the company's filings and listing, as of Oct 23, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Samarth Kulkarni
- Employees
- 393
- Listed since
- Oct 19, 2016
- Market value
- $4.8B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$4.67
- Dividend yield
- -
Company news
3 articles · newest first| Headline | Source | Date |
|---|---|---|
| CRISPR Therapeutics CFO Raju Prasad to step downThe company said Prasad is leaving to pursue external opportunities, and the announcement was made October 19, 2026. | Company release | Oct 19, 2026 |
| CRISPR Therapeutics to present CTX310 trial data at AHA 2026 Scientific SessionsThe late-breaking oral presentation covers patients with severe hypertriglyceridemia in a Phase 1b trial of the investigational therapy CTX310. | Company release | Oct 8, 2026 |
| CRISPR Therapeutics to present Phase 1 zugo-cel data in autoimmune diseaseThe therapy is an investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy targeting CD19. | Company release | Oct 2, 2026 |
Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover
Earnings
6 reported quarters · next on Nov 9, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 3, 2026 | -$0.94 | -$1.19 | $10.2M | $7.4M | EPS beat, GAAPRevenue beat |
| Q1 FY2026reported May 4, 2026 | -$1.28 | -$1.19 | $1.5M | $6.1M | EPS miss, GAAPRevenue miss |
| Q4 FY2025reported Feb 12, 2026 | -$1.37 | -$1.15 | $864K | $4.7M | EPS missRevenue miss |
| Q3 FY2025reported Nov 10, 2025 | -$1.17 | -$1.26 | $889K | $9.1M | EPS beat, GAAPRevenue miss |
| Q2 FY2025reported Aug 5, 2025 | -$2.40 | -$1.47 | $892K | $6.1M | EPS miss, GAAPRevenue miss |
| Q1 FY2025reported May 6, 2025 | -$1.58 | -$1.27 | $865K | $6.0M | EPS miss, GAAPRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| ARK Investment Management LLCCathie Wood | $516.0M | 9,460,939 | -16.4% | 9.80% |
| BlackRock, Inc. | $455.4M | 8,348,977 | +8.7% | 8.65% |
| Orbis Allan Gray Ltd | $297.2M | 5,449,161 | -10.8% | 5.65% |
| Capital World Investors | $259.0M | 4,749,525 | +0.5% | 4.92% |
| State Street Corp | $235.7M | 4,321,666 | +8.5% | 4.50% |
| GSK PLC | $175.7M | 3,220,627 | 0.0% | 3.34% |
| Geode Capital Management, LLC | $136.9M | 2,509,915 | +5.6% | 2.60% |
| T. Rowe Price Investment Management, Inc. | $112.0M | 2,053,017 | -30.5% | 2.13% |
| SR One Capital Management, LP | $111.2M | 2,038,763 | 0.0% | 2.11% |
| Two Sigma Investments, LP | $108.5M | 1,988,621 | +34.1% | 2.06% |
| FMR LLC | $104.1M | 1,908,503 | -2.4% | 1.98% |
| Sumitomo Mitsui Trust Group, Inc. | $93.8M | 1,720,734 | -7.2% | 1.78% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
10 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Samarth KulkarniChief Executive Officer | Sold | 47,837 | $49.78 | $2.4M | Oct 19, 2026filed Oct 20, 2026 | 1d |
| Simeon GeorgeDirector | Sold · scheduled | 14,514 | $49.63 | $720K | Oct 14, 2026filed Oct 16, 2026 | 2d |
| Samarth KulkarniChief Executive Officer | Sold | 4,098 | $49.26 | $202K | Oct 14, 2026filed Oct 15, 2026 | 1d |
| James R. KasingerGeneral Counsel and Secretary | Sold | 1,040 | $49.26 | $51K | Oct 14, 2026filed Oct 15, 2026 | 1d |
| James R. KasingerGeneral Counsel and Secretary | Sold · scheduled | 1,990 | $60.04 | $119K | Oct 6, 2026filed Oct 8, 2026 | 2d |
| James R. KasingerGeneral Counsel and Secretary | Sold · scheduled | 10,400 | $60.24 | $626K | Sep 22, 2026filed Sep 24, 2026 | 2d |
| Ali BehbahaniDirector | Sold | 13,679 | $57.09 | $781K | Sep 17, 2026filed Sep 21, 2026 | 2d |
| Naimish PatelChief Medical Officer | Sold | 3,786 | $55.62 | $211K | May 29, 2026filed Jun 1, 2026 | 1d |
| Samarth KulkarniChief Executive Officer | Sold | 10,020 | $46.78 | $469K | Mar 23, 2026filed Mar 24, 2026 | 1d |
| James R. KasingerGeneral Counsel and Secretary | Sold | 3,182 | $46.78 | $149K | Mar 23, 2026filed Mar 24, 2026 | 1d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Andrew Jacob SilverChief Financial Officer | Stock award | 25,000 | Oct 19, 2026 |
| Andrew Jacob SilverChief Financial Officer | Other Form 4 entry (see filing) | 95,374 | Oct 19, 2026 |
| Samarth KulkarniChief Executive Officer | Option exercise | 100,000 | Oct 16, 2026 |
| Simeon GeorgeDirector | Option exercise | 30,000 | Oct 14, 2026 |
| Samarth KulkarniChief Executive Officer | Option exercise | 8,333 | Oct 13, 2026 |
| James R. KasingerGeneral Counsel and Secretary | Option exercise | 2,113 | Oct 13, 2026 |
| James R. KasingerGeneral Counsel and Secretary | Option exercise | 1,990 | Oct 6, 2026 |
| James R. KasingerGeneral Counsel and Secretary | Option exercise | 10,400 | Sep 22, 2026 |
| Ali BehbahaniDirector | Option exercise | 30,000 | Sep 17, 2026 |
| Ali BehbahaniDirector | Other (see filing) | 75 | Aug 6, 2025 |
| Raju PrasadChief Financial Officer | Gift | 750 | Aug 7, 2026 |
| Douglas A. TrecoDirector | Stock award | 13,000 | Jun 5, 2026 |
| Christian RommelDirector | Stock award | 13,000 | Jun 5, 2026 |
| Briggs MorrisonDirector | Stock award | 13,000 | Jun 5, 2026 |
| Sandesh MahatmeDirector | Stock award | 13,000 | Jun 5, 2026 |
| Katherine A. HighDirector | Stock award | 13,000 | Jun 5, 2026 |
| John GreeneDirector | Stock award | 13,000 | Jun 5, 2026 |
| Harold Edward FlemingDirector | Stock award | 13,000 | Jun 5, 2026 |
| Maria FardisDirector | Stock award | 13,000 | Jun 5, 2026 |
| Ali BehbahaniDirector | Stock award | 13,000 | Jun 5, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in CRSP
3 disclosures · median 29d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Thomas R. Suozzi | Stock | Sale | $50,001 - $100,000 | -57.6%After the saleS&P 500 +74.5% · -132.0 pts vs S&P 500 | Sep 20, 2021 | Oct 5, 2021 | 15d |
| Thomas R. Suozzi | Stock | Purchase | $50,001 - $100,000 | -55.0%S&P 500 +81.4% · -136.5 pts vs S&P 500 | Jun 3, 2021 | Sep 23, 2021 | 112d |
| Marjorie Taylor GreeneJoint | Stock | Purchase | $1,001 - $15,000 | -73.3%S&P 500 +97.8% · -171.1 pts vs S&P 500 | Jan 21, 2021 | Feb 19, 2021 | 29d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in CRSP, filterable by party, chamber, type and account.
A congressional disclosure names a company by its ticker symbol alone, and a symbol can be reassigned after its previous holder leaves the market. One disclosure filed under CRSP is dated before this company began trading under it, and is not shown here.
Questions
Are insiders buying or selling CRSP?
Across the 10 most recent open-market filings shown here, 0 were purchases and 10 were sales. 3 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded CRSP?
Thomas R. Suozzi and Marjorie Taylor Greene disclosed CRSP transactions in the filings shown here.
How quickly are CRSP trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 29 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.